Hikal Limited
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are…
What Hikal files
- Others53
- Important34
- Investor Meet28
- Updates16
- Board Meeting12
- Dividend/Bonus8
Hikal's Board declared a final dividend of Rs. 0.40 per share for FY26, pending shareholder approval. Dividends are now taxable, with TDS deducted. Shareholders must update bank details and submit relevant tax documents by September 10 for appropriate tax withholding.
Hikal's promoter group entity, Castilia Life Sciences Pvt Ltd, transitioned to Castilia Life Sciences LLP. Its 3,02,31,914 equity shares (24.52% stake) in Hikal are now vested in the LLP. This is a structural change, not an ownership shift.
Hikal Ltd. declared an interim dividend of Re. 0.20 (10%) per equity share. Shareholders must submit relevant tax exemption declarations promptly to ensure lower tax deduction at source on the upcoming dividend payment.
Hikal Ltd. updated its internal code governing how designated persons trade company shares, aiming to strengthen compliance and transparency in trading activities.
Hikal's promoter group completed the amalgamation of Shri Rameshwara Investment and Shri Badrinath Investment into Castilia Life Sciences Private Limited. This consolidation led to a transfer of the company's equity shares.